Increased hepatic gluconeogenesis and type 2 diabetes mellitus

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Insulin resistance in type 2 diabetes mellitus (T2DM) leads to increased hepatic gluconeogenesis, a major cause of fasting hyperglycemia.
• Metformin, a primary T2DM drug, is known to reduce hepatic gluconeogenesis, but its precise mechanisms require further elucidation.

Purpose of the Study:

• To explain the role of elevated hepatic gluconeogenesis in T2DM pathogenesis.
• To review recently discovered mechanisms by which metformin attenuates hepatic gluconeogenesis.
• To analyze novel regulatory factors of gluconeogenesis for potential T2DM therapeutic strategies.

Main Methods:

• Literature review of studies on hepatic gluconeogenesis in T2DM.
• Analysis of research on metformin's molecular mechanisms of action.
• Synthesis of recent findings on gluconeogenesis regulatory pathways.

Main Results:

• Increased hepatic gluconeogenesis is a key factor in T2DM hyperglycemia.
• Metformin effectively reduces hepatic glucose production through various cellular pathways.
• Emerging determinants of gluconeogenesis offer new avenues for T2DM treatment.

Conclusions:

• Understanding metformin's action on hepatic gluconeogenesis is crucial for T2DM management.
• New insights into gluconeogenesis regulation may lead to innovative therapeutic approaches for type 2 diabetes mellitus.